drugset / Trial / NCT07159620
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
NaSingle-groupOpen-labelTreatment
Summary
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .
Timeline
- Start
- 2025-09-01
- Primary completion
- 2028-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 9 mg/m2 | Intravenous |
| Subject | Tucidinostat | Small molecule | 10 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Subject | Vindesine | Small molecule | 4 mg | Intravenous |